Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636245 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL636284 | 0.97 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL636510 | 0.96 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL636524 | 0.95 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL636253 | 0.94 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL6032767 | 0.93 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL4399942 | 0.93 | PDE10A (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL637328 | 0.93 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL636539 | 0.93 | PDE10A (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL637298 | 0.92 | HCRTR1 (0.37) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203778-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-08 | — | — | US | claimed |
| EP-2549998-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | Glenmark Pharmaceuticals S.A. (CH) | 2013-01-30 | — | — | EP | claimed |
| WO-2011117711-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-09-29 | — | — | WO | claimed |
| US-20130203778-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-08 | — | — | US | disclosed |
| EP-2549998-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | Glenmark Pharmaceuticals S.A. (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117711-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203778-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRIMIDINEONE DERIVATIVE | GPR17, P2RY2, ABCG2 | HCRTR1 2154/4885HCRTR2 1097/4885CYP3A4 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.